US FDA pre submission meetings are part of the Q-Submission Program. It allows medical device manufacturers to obtain structured, written feedback and optional meetings with FDA reviewers. These meetings are conducted before submitting applications, such as 510(k), De...
The US FDA accepts MDSAP audits in lieu of routine inspections. Hence, a single MDSAP audit can demonstrate compliance with both ISO 13485:2016 and FDA’s Quality System Regulation (21 CFR Part 820). For manufacturers, this reduces the burden of undergoing separate FDA...
Medical device benefit-risk analysis is a structured evaluation of whether the clinical benefits of a device outweigh its residual risks. It is mandated under ISO 14971:2019, FDA regulations, and EU MDR. Thus, it is critical for regulatory approval, patient safety,...
FDA design and development planning is a structured process mandated under 21 CFR Part 820 (Quality System Regulation). It serves as the mandated roadmap for controlling a medical device’s progression from initial concept to a validated product. It ensures...
The US FDA classifies Software as a Medical Device (SaMD) using a risk-based framework. It places software into four classes (I–IV). Class IV represents the highest risk (life-critical decisions). On the other hand, Class I represents the lowest (supportive,...